Aurinia Pharmaceuticals Inc (AUPH) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 8.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 49.5 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
Even with a 75/100 (B) score, AUPH faces multiple-compression risk if 8.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($16.49) or 200D SMA ($15.65) invalidates the momentum regime and cuts Target Base ($18.53) toward Bear Floor ($14.11).
Aurinia Pharmaceuticals Inc (AUPH) slipped -0.86% to $17.21, trading at 68% of its 52-week range ($12.79 – $19.25). High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support.
Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Friday reported third-quarter net income of $31.
EDMONTON, Alberta, October 30, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress
Aurinia Pharmaceuticals (NASDAQ:AUPH) raises FY2026 sales outlook from $315.000 million-$325.000 million to $325.000 million-$330.000 million vs $330.261 million estimate.
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.22 by 4.55 percent. This is unchanged from the same period last year. The company
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AUPH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AUPH. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Aurinia Pharmaceuticals Inc (AUPH) ranks #44 by composite RQD confidence (75/100, grade B) and #237 by equity capitalization ($2.29B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with AUPH at 75/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AUPH
ACTIVE
Aurinia Pharmaceuticals Inc | B | 75/100 | 8.0x | 88.5% | 16.5% | -0.86% | $2.29B | Benchmark Subject |
| PBH Prestige Consumer Healthcare Inc. | B | 72/100 | 12.1x | 54.7% | 13.8% | +2.01% | $2.31B | /pbh-vs-auph → |
| HRMY Harmony Biosciences Holdings Inc. | B+ | 80/100 | 14.2x | 77.2% | 63.0% | +0.23% | $2.25B | /hrmy-vs-auph → |
| SDGR Schrodinger Inc. | D- | 43/100 | — | 55.7% | -35.0% | -2.85% | $2.24B | /sdgr-vs-auph → |
| PHVS Pharvaris N.V. | C | 63/100 | — | — | — | +2.32% | $2.34B | /phvs-vs-auph → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aurinia Pharmaceuticals Inc (AUPH) reported GAAP revenue of $283.1M (+20.4% vs. FY2024 revenue of $235.1M , and +61.3% cumulative change since FY2023) , GAAP net income of $287.2M, operating cash flow of $135.7M, and free cash flow of $135.7M (+205.6% YoY). On the balance sheet, AUPH closed FY2025 with $751.6M in total assets against $0 in total debt (Altman Z-Score: 8.33, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $283.1M | $287.2M | $135.7M | $135.7M | $751.6M | — |
| FY2024 (FY) | 2024-12-31 | $235.1M | $5.8M | $44.4M | $44.4M | $550.6M | — |
| FY2023 (FY) | 2023-12-31 | $175.5M | -$78.0M | -$33.5M | -$33.5M | — | — |
As of 2026-11-01, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $17.21 (-0.86% 1D, market cap $2.29B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 18/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AUPH ranks #44 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AUPH carries a Roarable B (75/100 RQD), trailing P/E of 8.0x, gross margin of 88.5%, and ROIC of 16.5%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a B grade (72/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.31B) and HRMY (Harmony Biosciences Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 14.2x, ROIC 63.0%, cap $2.25B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
Per AUPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001600620), Aurinia Pharmaceuticals Inc generated $283.1M in revenue (+20.4% YoY), $287.2M in net income, and $135.7M in free cash flow against $751.6M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
AUPH last traded at $17.21 (-0.86% on volume of 744,753 shares), positioning the stock +4.37% above its 50-day simple moving average ($16.49) and +9.97% above its 200-day simple moving average ($15.65). Across its 52-week range of $12.79 to $19.25, AUPH sits at the 68.4% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($16.18 to $18.24).
Why AUPH Stock slipped -0.86% Today — RQD Quant Desk Flash. High-quality cash engine (89% profit margin, 17% return on capital) with steady institutional support.